Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium
November 19 2019 - 9:05AM
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer and related conditions,
announced today that its abstract for the Phase III study of oral
paclitaxel and encequidar (Oral Paclitaxel) in metastatic breast
cancer has been selected for the press program of the 2019 San
Antonio Breast Cancer Symposium (SABCS). The Company will deliver
an oral presentation at SABCS, taking place in San Antonio, Texas,
on Friday, December 13, 2019. After the oral presentation, the
Company plans to discuss the results in a Key Opinion Leader (KOL)
webcast event for the investment community.
“We look forward to presenting additional data and analyses at
SABCS from the pivotal Phase III study of Oral Paclitaxel in
metastatic breast cancer,” said Dr. Johnson Lau, Athenex’s Chairman
and Chief Executive Officer. “We are excited by the opportunity to
share these updates with oncologists, patients and researchers to
highlight Oral Paclitaxel’s potential to positively impact outcomes
for people living with metastatic breast cancer.”
Oral Presentation
Details: |
Abstract Title: |
Oral Paclitaxel with Encequidar: The first orally
administered paclitaxel shown to be superior to IV paclitaxel on
confirmed response and survival with less neuropathy: a Phase III
clinical study in metastatic breast cancer. |
Session: |
General Session 6 |
Date and Time: |
Friday, December 13, 2019 at
3:15pm CT |
Location: |
Hall 3 / Henry B. Gonzalez
Convention Center, San Antonio, Texas |
For more information,
please visit
https://www.sabcs.org/Program/Daily-Schedule/Day-4 |
Abstracts that have been selected for the press program will
only have titles posted to the SABCS website until the embargo
lifts on December 13, when the complete abstract will post
online.
KOL Webcast Event
On December 13, 2019, after the oral presentation, the Company
plans to review the Phase III clinical data presented at SABCS
during a webcasted event for the investment community. Further
details will be made available in a separate announcement.
Athenex Exhibit Booth
Attendees at SABCS are invited to visit the exhibit booth hosted
by Athenex Oncology at the conference (booth #627/629), December 10
to 13, from 10:45am to 5pm CT daily.
The Orascovery platform was initially developed by Hanmi
Pharmaceuticals and licensed exclusively
to Athenex for all major worldwide territories
except Korea, which is retained by Hanmi.
About Athenex, Inc.Founded in 2003, Athenex,
Inc. is a global clinical stage biopharmaceutical company dedicated
to becoming a leader in the discovery, development and
commercialization of next generation drugs for the treatment of
cancer. Athenex is organized around three platforms, including an
Oncology Innovation Platform, a Commercial Platform and a Global
Supply Chain Platform. The Company’s current clinical pipeline is
derived from four different platform technologies: (1) Orascovery,
based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase
inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4)
Arginine deprivation therapy. Athenex’s employees worldwide are
dedicated to improving the lives of cancer patients by creating
more active and tolerable treatments. Athenex has offices in
Buffalo and Clarence, New York; Cranford, New Jersey; Houston,
Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple
locations in Chongqing, China; Manchester, UK; Guatemala City,
Guatemala and Buenos Aires, Argentina. For more information, please
visit www.athenex.com.
Forward-Looking StatementsExcept for historical
information, all of the statements, expectations, and assumptions
contained in this press release are forward-looking statements.
These forward-looking statements are typically identified by terms
such as “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,”
“plan,” “potential,” “predict,” “preliminary,” “probable,”
“project,” “promising,” “seek,” “should,” “will,” “would,” and
similar expressions. Actual results might differ materially
from those explicit or implicit in the forward-looking statements.
Important factors that could cause actual results to differ
materially include: the development stage of our primary clinical
candidates and related risks involved in drug development, clinical
trials, regulation, manufacturing and commercialization; our
reliance on third parties for success in certain areas of Athenex’s
business; our history of operating losses and need to raise
additional capital to continue as a going concern; our ability to
integrate CIDAL’s assets into our existing operations; competition;
intellectual property risks; risks relating to doing business in
China; the uncertainty of when, if at all, we will be able to
resume producing API in our Chongqing plant; and the other risk
factors set forth from time to time in our SEC filings, copies of
which are available for free in the Investor Relations section of
our website at
http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or upon
request from our Investor Relations Department. All information
provided in this release is as of the date hereof and we assume no
obligation and do not intend to update these forward-looking
statements, except as required by law.
CONTACTSInvestor Relations:Tim McCarthyManaging
Director, LifeSci Advisors, LLCDirect: 212-915-2564
Athenex, Inc.:Randoll SzeChief Financial OfficerEmail:
RandollSze@athenex.com
Jacqueline LiCorporate Development and Investor RelationsEmail:
JacquelineLi@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Sep 2023 to Sep 2024